Almac Signs Multiple New Trials

Yardley, PA-May 20, 2008-Almac Clinical Technologies (www.almacgroup.com) announced today that it has signed $12m worth of new studies within the past several weeks, including one of the largest studies in the company’s history. This new global mega-study will involve close to 20,000 patients and requires provision of very sophisticated technological and statistical solutions, a key strength of Almac service offering.

Almac Clinical Technologies, one of the five divisions of the Almac Group, has grown rapidly over the past few years, with growth rates accelerating further this year. The firm has recently signed a record number of new bookings, including a mix of large global studies. Almac Clinical Technologies President Jim Murphy attributes that growth to market trends which play to the strengths of Almac.  He said: “We are seeing an increase in the number of large, global, complex trials as well as smaller adaptive clinical trials, each requiring sophisticated randomization and drug management approaches. Sponsors seem to be turning to experienced global firms, such as Almac, with strong project management expertise and technologies to make those trials successful.”

Jim Murphy believes that Almac’s financial stability contributes to the firm’s attractiveness to sponsors planning large studies that will be carried out over many years. Murphy: “Clients want to know that the firm providing essential services for their trial is financially stable and is going to be around for many years. We were founded in 1995 and are a part of the greater Almac Group, a large global provider of R&D services that is privately-owned, growing rapidly, and well-financed. This assures our clients that we are going to be there for them in the future and will continue to invest in ways to support their trials.”

Almac Clinical Technologies’ Business Development Director, Joe Cunningham, comments on another trend that seems to be fueling the firm’s rapid growth. Cunningham: “Over the past year we have seen a split in the marketplace with an increasing number of complex and larger trials that require sophisticated statistical methodologies and technological solutions. We are able to handle these through our highly customizable and configurable IXR Interactive Voice and Web Response systems. We are also experiencing higher volumes of studies that fit our IXR Express offering which provides flexible core module based solutions that enable faster set-up times and lower costs for a web and phone solution. Because we have highly trained sales and project managers who work consultatively with our clients to find the appropriate solution for their trial, we are satisfying clients’ needs across the board, from emerging biotechs to top 10 pharmaceutical firms.”